Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.
1. A pharmaceutical formulation for oral administration comprising a pharmaceutically acceptable excipient and a hydrochloride salt of MP470, wherein the MP470 has the following structure:
2. The pharmaceutical formulation of claim 1 , wherein the HCl salt of MP470 comprises a crystalline form characterized by an X-ray diffraction pattern having diffraction peaks (2θ) at 8.1°, 13.0°, and 24.6°.
3. The pharmaceutical formulation of claim 2 wherein said salt is further characterized by a melting endotherm of 180-210° C. as measured by differential scanning calorimetry at a scan rate of 10° C. per minute.
4. The pharmaceutical formulation of claim 2 wherein said salt is further characterized by a melting endotherm of 185-200° C. as measured by differential scanning calorimetry at a scan rate of 10° C. per minute.
5. The pharmaceutical formulation of claim 1 , wherein the HCl salt of MP470 comprises a crystalline form characterized by an X-ray diffraction pattern having diffraction peaks (2θ) at 9.5°, 10.4°, 11.4°, 14.1°, and 25.5°.
6. The pharmaceutical formulation of claim 1 wherein the pharmaceutical composition is in a solid form in which the salt is mixed with carriers or a liquid form in which the salt is dissolved.
7. The pharmaceutical formulation of claim 6 wherein the salt is dissolved in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or a combination thereof.
8. The pharmaceutical formulation of claim 6 wherein the pharmaceutical formulation is an aqueous solution in which the salt is dissolved.
9. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is in an oral dosage form.
10. The pharmaceutical formulation of claim 9 , wherein the oral dosage form is tablet, capsule, suspension or liquid.
11. A pharmaceutical formulation for oral administration comprising a pharmaceutically acceptable excipient and a hydrochloride salt form of MP470, wherein the MP470 has the following structure:
and wherein the salt form of MP470 in the formulation has a decreased toxicity and an increased oral bioavailability relative to the free base form of MP470.
12. The pharmaceutical formulation of claim 11 , wherein the increased oral bioavailability is at least 50% higher than in the free base form of MP470.
13. The pharmaceutical formulation of claim 11 , wherein the increased oral bioavailability is at least 75% higher than in the free base form of MP470.